A system for facial and skin treatment includes a universal skin exfoliating and rejuvenating system that uses dual-function plate mounted onto the front edge of the hand-held system in a multi-step process. One step used in the multi-step process includes of a microdermabrasion procedure using diamond-tipped wands fixed on a dual-function plate to cleanse and exfoliate dead skin that simultaneously removes the dead skin away. In another dual-function process, a plate equipped with micro-needles and skin care products is used to generate collagen for firmer toned skin. The micro-needles are fixed on moving parts or roller, to help with fine lines, wrinkles, and large pores. Also, a dual-function plate is used for skin massage and special serum treatment and application. The handheld system is equipped with a miniature vacuum pump, mini supply containers, and control parts to supply serums and skincare products to the dual-function plates.

Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface. In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent. In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components. In some cases, the tissue interfacing component may comprise and/or be associated with the pharmaceutical agent.

Chimeric antigen receptor T cells (CAR T) therapy reached a milestone in eradicating B-cell malignancies, but beneficial effects in solid tumors are not obtained yet. A porous microneedle patch is disclosed that carries CAR T cells to solid tumors (or other cell types). The device is a honeycomb-like porous microneedle patch that accommodates CAR T cells and allows in situ penetration-media seeding of CAR T cells within post-surgical resection of solid tumors. CAR T cells loaded in the pores of the microneedle tips were readily escorted to the tumor in an evenly scattered manner without losing their activity. Such microneedle-mediated local delivery enhanced infiltration and immune stimulation of CAR T cells as compared to direct intratumoral injection. This tailorable patch offers a transformative platform for scattered seeding of living cells for treating a variety of diseases. Other cell types may be loaded into the porous microneedles.

Disclosed are a microneedle patch and a method for fabricating the microneedle patch. The microneedle patch includes a base layer including a mesh structure or auxetic materials having a negative Poisson's ratio, and a microneedle array disposed on the base layer. The method includes forming a base layer including a mesh structure or auxetic materials having a negative Poisson's ratio, and forming a microneedle array on the base layer.

Disclosed herein are devices (e.g., needles (e.g., hollow needles), hollow staples, articles, apparatuses, and systems), kits, and methods for treating skin and skin conditions, for example, by promoting skin tightening, such as by reducing skin laxity and reducing tissue area or volume.

Disclosed herein are compositions, devices and methods employing therapeutic concentrations of psilocybin, LSD or MDMA for the treatment of certain health conditions, including depression, anxiety, post-traumatic stress disorder, migraine and cluster headache. Also described are methods and apparatuses to deliver psilocybin, LSD or MDMA by intracutaneous administration via microneedle administration.

Provided is an inexpensive microneedle array with little dimensional error that can control, with high precision, the amount of a predetermined component to be introduced to the inner part of the skin, and a production method for this microneedle array. A foundation that is insoluble or sparingly soluble in inner part of the skin is overlaid on a mold. A plurality of frustum-shaped protrusions, which are insoluble or sparingly soluble in the raw material liquid, provided on a first main surface of the foundation are fit into a plurality of cone-shaped recesses. The raw material liquid in the plurality of cone-shaped recesses dries and, as a result, a plurality of microneedles, which are dissolvable in the inner part of the skin, are fixed to tip surfaces of the plurality of frustum-shaped protrusions.

A method for manufacturing a microprojection unit (10) according to the invention involves: a microprojection tool forming step of forming a microprojection tool (1) by bringing a projecting mold part (11) into contact from one surface (2D) side of a base sheet (2A) including a thermoplastic resin, and thus forming a protrusion (3) that protrudes from another surface (2U) side, and withdrawing the projecting mold part (11) from the interior of the protrusion (3); a joining step of joining the one surface (2D) side of the base sheet (2A), in which the microprojection tool (1) has been formed, and a tip end of a base component (4); and a cutting step of cutting the base sheet (2A), to which the base component (4) has been joined, along a contour (4L) of the base component (4) at a position more inward than the base component's contour (4L) in a planar view of the base sheet (2A) as viewed from the microprojection tool (1) side, to manufacture a microprojection unit (10).

The present invention relates to a microneedle system (MNS) for the intradermal delivery of interferon, wherein polyvinylpyrrolidone is the major constituent of a completely soluble formulation.

A microneedle device of the present invention comprises a substrate, microneedles disposed on the substrate, and a coating formed on the microneedles, wherein the coating comprising dexmedetomidine or a pharmaceutically acceptable salt thereof and isoproterenol or a pharmaceutically acceptable salt thereof. Using said microneedle device, a fast increase rate of dexmedetomidine concentration in plasma after application of the microneedle device is achieved.